Ignite Creation Date:
2025-12-24 @ 5:39 PM
Ignite Modification Date:
2026-01-03 @ 7:16 PM
Study NCT ID:
NCT03276468
Status:
COMPLETED
Last Update Posted:
2023-01-10
First Post:
2017-09-07
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas
Sponsor:
The Lymphoma Academic Research Organisation
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-02-12
Start Date Type:
ACTUAL
Primary Completion Date:
2019-09-19
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-08-24
Completion Date Type:
ACTUAL
First Submit Date:
2017-09-07
First Submit QC Date:
None
Study First Post Date:
2017-09-08
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-01-09
Last Update Post Date:
2023-01-10
Last Update Post Date Type:
ACTUAL